Should I buy Halozyme (HALO) stock or is it too late?

Halozyme · Health Care · price $107

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 70% of its targets hit on this sector (238 calls tested). It aims for $115 (+7.6 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).

The 3 reliable analysts $105-1.8 %

The 3 other firms $93-13 %

How to read it: the 3 reliable firms are not filtered by optimism — 1 aim above the price, 2 below, hence their $105 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Halozyme

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	100 %	+57.4 %	5	$53 -50%
JP Morgan	70 %	+53.4 %	10	$65 -39%
HC Wainwright & Co.	100 %	+32.9 %	37	$115 +8%
Benchmark	75 %	+30.3 %	8	$90 -16%
JMP Securities	64 %	+18.5 %	14	$91 -15%
Morgan Stanley	60 %	+13.0 %	10	$93 -13%
Wells Fargo	67 %	+9.6 %	6	$95 -11%
BMO Capital	80 %	+75.9 %	5	—

In short — Should you invest in Halozyme? Is it too late, still worth it? Analysts are overwhelmingly positive (83% buy, median target $100, i.e. -6%), and the most reliable on HALO targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

83% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
The most reliable firm on HALO, HC Wainwright & Co. (100% hit rate, 37 scored calls), targets $115 (call made on August 7, 2026, maturing on August 7, 2027) (+8%) in its most recent call, and $85 (call made on September 22, 2025, maturing on September 22, 2026) (-21%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 6 ratings, 1 is neutral.
Limited upside: the median target is only -6% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on HALO

Median target $100 (-6%) · 6 ratings · Buy consensus

Strong Buy00%

Buy583%

Hold117%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Halozyme now?

We won't decide for you. The facts: 83% of analysts rate it a buy, median target $100 (-6%), and HC Wainwright & Co. (most reliable on HALO, 100%) targets $115. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Halozyme?

The stated upside is small: the median target ($100) sits just -6% from the price ($107) (most reliable on HALO: HC Wainwright & Co., 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Halozyme still worth investing in?

It depends on the gap between the price ($107) and its estimated value: analysts target $100 on median (-6%), with 83% buys (most reliable on HALO: HC Wainwright & Co., 100%). Cross-check with their real reliability on HALO and the cautions above. Information, not advice.

What's the main risk in buying HALO?

The consensus is not unanimous: of 6 ratings, 1 is neutral.

→ Go deeper: the full Halozyme profile (consensus, analyst reliability, price target, performance).